Human Genome Sciences Inc v Eli Lilly & Co

A patent for a newly identified protein was capable of industrial application, because its likely uses were plausible on the basis of the patent and the common general knowledge.

Citation
[2011] UKSC 51, [2012] RPC 6
Court
Supreme Court
Year
2011
Subject
Intellectual Property Law
Topic
Patents: patentability and validity

Facts

Human Genome Sciences held a patent for a nucleotide sequence encoding a newly discovered protein, Neutrokine-α, which belonged to a family of proteins known to have roles in the immune system. The patent described possible uses of the protein, which were based on its likely biological function. Eli Lilly argued that the patent was invalid because the invention was not susceptible of industrial application, since its uses were speculative.

Legal principle

The Supreme Court held that the patent was valid. Lord Neuberger said that the court should follow the approach of the Technical Board of Appeal of the European Patent Office, under which the patent must disclose a practical application and some profitable use for the claimed substance, so that the ensuing monopoly can be expected to lead to some practical benefit. A plausible or reasonably credible claimed use, or even an educated guess, can suffice. Given the known functions of the family of proteins to which the new protein belonged, its likely uses were plausible.

Related cases on patents: patentability and validity

Studying intellectual property law? Our tutors help you understand and apply cases like this in essays, problem questions and exams. Request a quote or browse our law notes.

Back to all law cases

This summary is for study and revision and is not legal advice. Although our case summaries are checked for accuracy, we do not guarantee that they are free from errors or omissions. Always read the full judgment for the court's reasoning.

Contact Us

Enquire about our bespoke academic solutions